Disclosed herein are compositions and methods of use thereof for the treatment of mastitis in dairy cattle. The compositions and methods can have improved effectiveness and duration of activity against mastitis-causing bacteria. In particular embodiments, the methods include treating mastitis infection by intramammary infusion of a disclosed composition.

Disclosed herein are compositions and methods of use thereof for the treatment of mastitis in dairy cattle. The compositions and methods can have improved effectiveness and duration of activity against mastitis-causing bacteria. In particular embodiments, the methods include treating mastitis infection by intramammary infusion of a disclosed composition.

Disclosed herein are compositions and methods of use thereof for the treatment of mastitis in dairy cattle. The compositions and methods can have improved effectiveness and duration of activity against mastitis-causing bacteria. In particular embodiments, the methods include treating mastitis infection by intramammary infusion of a disclosed composition.

The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X.sup.1, X.sup.4, R.sup.1, R.sup.2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (α4β1) and alpha-V-beta-3 (α Vβ3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins. ##STR00001##

The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X.sup.1, X.sup.4, R.sup.1, R.sup.2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (α4β1) and alpha-V-beta-3 (α Vβ3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins. ##STR00001##

The present disclosure relates to compounds comprising as β-hydroxybutyric acid, and a weakly basic polymer. The disclosure also includes methods for inducing nutritional ketosis comprising administering the compounds or compositions to a mammal in need thereof.

The present disclosure relates to compounds comprising as β-hydroxybutyric acid, and a weakly basic polymer. The disclosure also includes methods for inducing nutritional ketosis comprising administering the compounds or compositions to a mammal in need thereof.

An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the SCS. The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.

In various aspects and embodiments, the present invention provides hemostatic products and methods for treating wounds, including cavity wounds and non-compressible hemorrhage. In various embodiments, the invention employs hydrophobically-modified polymer foams, gels, or pastes.

Disclosed herein is a compound of formula I:

##STR00001##

where m, n and R.sup.1 are as defined herein. Also disclosed herein are uses of the compound.